[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-367451-105":59,"doc-detail-367451-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","circulating-tumour-dna-as-a-promising-biomarker-for-breast-cancer-diagnosis-treatment-monitoring","Circulating tumour DNA as a promising biomarker for breast cancer diagnosis & treatment monitoring","","Breast cancer mortality among women makes monitoring residual disease and extending lead time for relapse detection in high-risk patients clinically crucial. Minimally invasive approaches using circulating biomarkers are being developed for diagnosis, prognosis, and therapeutic-response monitoring. Among them, circulating tumour DNA (ctDNA) is highlighted as a liquid-biopsy biomaterial that may mirror tumour evolution, yet clinical use is limited by incomplete knowledge of its biological properties. This review summarizes ctDNA characteristics and its translational and clinical role, emphasizing the need for robust, standardized assessment methods.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/circulating-tumour-dna-as-a-promising-biomarker-for-breast-cancer-diagnosis-treatment-monitoring/367451/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/circulating-tumour-dna-as-a-promising-biomarker-for-breast-cancer-diagnosis-treatment-monitoring/367451.png","ImageObject",300,407,{"name":92,"@type":93},"Aria Callaghan","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is monitoring residual disease important in breast cancer?","Question",{"text":112,"@type":113},"Monitoring residual disease helps extend the lead time to detect relapse in high-risk patients, supporting more timely clinical decisions.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What makes ctDNA promising as a biomarker?",{"text":117,"@type":113},"ctDNA is considered to mirror tumour evolution and can act as a non-invasive, real-time surrogate for tumour tissue-based biomarkers.",{"name":119,"@type":110,"acceptedAnswer":120},"What limits the clinical utilisation of ctDNA today?",{"text":121,"@type":113},"Its adoption is hindered mainly by gaps in knowledge of ctDNA’s biological properties and specific characteristics, requiring robust and standardized assessment methods.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},367451,1790815927,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962084926284,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Indian J Med Res 161, March 2025, pp 267-277 DOI: 10.25259/IJMR_ 1291_2024  \nReview Article  \nCirculating tumour DNA as a promising biomarker for breast cancer diagnosis & treatment monitoring  \nRiddhi Ursekar1, Rohan Chaubal1,2,3, Khushboo A. Gandhi 1, Elizabeth Talker1,4, Jaya Chitra1,3, Aishwarya Raja1,2,4, Rushikesh Sunil Mukhare1,2,4, Ankita Singh1, Anushree Kadam1, Mrudula Madhav1, Shwetali Pandey1, & Sudeep Gupta1,2,4  \n1Clinical Genomics and Hypoxia Lab (Clinician Scientist Laboratory), Advanced Centre for Treatment, Research, and Education in Cancer, Tata Memorial Centre, 2Homi Bhabha National Institute, Training School Complex, Departments of 3Surgical Oncology & 4Medical Oncology, Tata Memorial Hospital, Tata Memorial Centre, Mumbai, Maharashtra, India  \nReceived August 29, 2024; Accepted January 31, 2025; Ahead of print April 23, 2025; Published April 29, 2025  \nBreast cancer contributes a large fraction to mortality among women diagnosed with cancer. It is important to monitor residual disease and extend the lead time to detect relapse in high-risk patients.  \nMinimally invasive techniques that utilise circulating biomarkers are being explored for their potential in diagnosis, prognosis, and disease monitoring of breast cancer. Circulating biomarkers have been investigated as tools for breast cancer diagnosis, prognosis, prediction, and monitoring of therapeutic response and resistance. Among these, circulating tumour cells and cell-free plasma DNA (cfDNA) derived from tumour cells (circulating tumour DNA i.e. ctDNA) have been integrated into clinical trial designs. Among all circulating biomarkers, ctDNA stands out as a promising biomaterial with great potential as it is thought to mirror the tumour's evolution. However, its clinical utilisation is hampered mainly by gaps in knowledge of its biological properties and specific characteristics. The development of robust and standardised methods for assessing circulating biomarkers is essential for realising the potential of personalised medicine. This review aims to summarise the characteristics of ctDNA and its role in breast cancer, drawing from both basic and translational research to provide insights into its clinical application. This review suggests that ctDNA has the potential to be a non-invasive, real-time surrogate for tumour tissue-based biomarkers. In conclusion, circulating biomarkers have the potential to revolutionise breast cancer diagnosis, prognosis, and treatment monitoring, but the development of standardised methods for their assessment is essential. ctDNA, in particular, shows great promise as a liquid biopsy tool, but further research is needed to understand its biology and ensure its clinical utility  \nfully.  \nKey words Biomarkers-breast cancer-cell free DNA-circulating tumour DNA-diagnosis-liquid biopsy  \nSite-specific tumour biopsies are analysed to determine the best treatment for various cancers. However, the data obtained from a biopsy are transient,  \nand the initial tumour cannot be used to examine mutations acquired during treatment or resistance development. Studies have identified up to 25 per cent  \n© 2025 Indian Journal of Medical Research, published by Scientific Scholar for Director-General, Indian Council of Medical Research  \nThis open access publication is protected under CC-BY-NC-SA 4.0  \n268 INDIAN J MED RES, MARCH 2025  \nof subtype mutations during or post-disease progression after anticancer treatment1. While tumour biopsy remains the gold standard for diagnosis, classifying patients, and treatment selection, liquid biopsy i.e., detection and monitoring of the cancer genome in blood samples-is advancing precision medicine. Circulating tumour cells/DNA (CTCs/ctDNA) and exosomes found in processed liquid biopsies elucidate tumour development, resistance, and heterogeneity during therapy without invasive collection procedures or sampling bias1. Thus, liquid biopsies would be the only way to accurately diagnose the tumour a","cbCaiqYsQQESpfb5","https://ap.wps.com/l/cbCaiqYsQQESpfb5","pdf",474586,11,"English","# Introduction\n## Need for monitoring and precision medicine\n# Circulating biomarkers and ctDNA rationale\n## Tumour evolution and clinical integration\n# Origins and release mechanisms of ctDNA\n## cfDNA, tumour mutations, and heterogeneity\n# Clinical applications in breast cancer\n## Diagnosis, therapy response, MRD and relapse","[{\"question\":\"Why is monitoring residual disease important in breast cancer?\",\"answer\":\"Monitoring residual disease helps extend the lead time to detect relapse in high-risk patients, supporting more timely clinical decisions.\"},{\"question\":\"What makes ctDNA promising as a biomarker?\",\"answer\":\"ctDNA is considered to mirror tumour evolution and can act as a non-invasive, real-time surrogate for tumour tissue-based biomarkers.\"},{\"question\":\"What limits the clinical utilisation of ctDNA today?\",\"answer\":\"Its adoption is hindered mainly by gaps in knowledge of ctDNA’s biological properties and specific characteristics, requiring robust and standardized assessment methods.\"}]","Circulating tumour DNA as a promising biomarker for breast cancer diagnosis & treatment monitoring | PDF",1790170841,28,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/922bca6baf4fca911ec18b55644baaa2.webp",983,1272,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dda2020170299c196617b5e88f029b37.webp",982,1270,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bcc0601036480f049b70eb780d04e0e2.webp",981,1269,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/be2a28cce14442355d75795c711ed743.webp",980,1268]